UA Home | AHSC
College of MedicineCalendar : Directories : A-Z Index : Library : Streaming Video : What’s New

Information For:

 

 

Welcome

Arizona Cancer Center researcher announces results of clinical trial

Researchers announced today that the combination of a low dosage of the targeted agent difluoromethylornithine (DFMO) and sulindac, a non-steroidal anti-inflammatory drug (NSAID), has been shown to reduce the risk of recurrent colorectal polyps, a precursor to colon cancer, by up to 95 percent with minimal toxicity.

“Combination chemoprevention with DFMO and sulindac can substantially reduce colon polyp recurrence, especially those polyps associated with the greatest risk of colorectal cancer,” says Eugene W. Gerner, Ph.D, director of the Arizona Cancer Center’s Gastrointestinal (GI) Cancer Program and the National Cancer Institute-funded Specialized Program of Research Excellence (SPORE) in GI Cancers at the University of Arizona College of Medicine. Dr. Gerner is also a member of the BIO5 Institute at the University of Arizona.

Dr. Gerner and Frank Meyskens, MD, director of the Chao Family Cancer Center at the University of California at Irvine, announced their research results earlier today at the annual meeting of the American Association for Cancer Research (AACR) in San Diego. The research results also were published online this week in the inaugural issue of the AACR’s new journal, Cancer Prevention Research.
Read More >>